Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study

Table 5 Relative healthcare cost per month by baseline SHPT parameters, Hungary, Italy, Portugal, Spain, and Turkey

Baseline level*	n	Relative cost coefficient (95% CI)
Baseline level*	n	Univariate analysis^†	Multivariate analysis^‡
iPTH, pg/mL
< 75	1054	1.01 (0.92, 1.12)	0.98 (0.89, 1.09)
≥ 75 – < 150	1145	0.98 (0.89, 1.08)	1.00 (0.91, 1.10)
≥ 150 – ≤ 300 (reference)	1394	1.00	1.00
> 300 – ≤ 600	1140	1.11 (1.01, 1.22)	1.11 (1.01, 1.22)
> 600	653	1.53 (1.36, 1.71)	1.41 (1.25, 1.59)
Total calcium (mmol/L)
< 2.10 mmol/L	833	1.06 (0.97, 1.17)	1.01 (0.92, 1.11)
≥ 2.10 – ≤ 2.37 mmol/L (reference)	2980	1.00	1.00
> 2.37 mmol/L	1405	1.14 (1.06, 1.24)	1.08 (1.00, 1.17)
Missing	168	1.26 (1.03, 1.54)	1.54 (1.18, 2.00)
Phosphate (mmol/L)
< 1.13 mmol/L	827	0.75 (0.68, 0.82)	0.75 (0.68, 0.82)
≥ 1.13 – ≤ 1.78 mmol/L (reference)	3104	1.00	1.00
> 1.78 mmol/L	1208	1.39 (1.28, 1.51)	1.38 (1.27, 1.50)
Missing	247	0.94 (0.79, 1.12)	0.70 (0.55, 0.88)

iPTH, intact parathyroid hormone.
*Mean during 3-month baseline period.
^†Adjusted for duration of follow-up.
^‡Adjusted for iPTH, total calcium, phosphate, duration of follow-up, age, sex, chronic kidney disease aetiology, history of cardiovascular disease, diabetes and cancer, dialysis vintage, C-reactive protein, albumin, haemoglobin, ferritin, total cholesterol and blood leukocyte count.

ISSN: 1471-2369